108 related articles for article (PubMed ID: 24606705)
1. Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.
Da Silva DM; Movius CA; Raff AB; Brand HE; Skeate JG; Wong MK; Kast WM
Virology; 2014 Mar; 452-453():279-86. PubMed ID: 24606705
[TBL] [Abstract][Full Text] [Related]
2. MIP3 alpha stimulates the migration of Langerhans cells in models of human papillomavirus (HPV)-associated (pre)neoplastic epithelium.
Herman L; Hubert P; Caberg JH; Evrard B; Kedzia W; Boniver J; Delvenne P
Cancer Immunol Immunother; 2007 Jul; 56(7):1087-96. PubMed ID: 17146629
[TBL] [Abstract][Full Text] [Related]
3. Chlamydia trachomatis enhances HPV persistence through immune modulation.
Lu Y; Wu Q; Wang L; Ji L
BMC Infect Dis; 2024 Feb; 24(1):229. PubMed ID: 38378486
[TBL] [Abstract][Full Text] [Related]
4. The association of cervicovaginal Langerhans cells with clearance of human papillomavirus.
Dai W; Gui L; Du H; Li S; Wu R
Front Immunol; 2022; 13():918190. PubMed ID: 36311788
[TBL] [Abstract][Full Text] [Related]
5. Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth.
Heeren AM; Rotman J; Samuels S; Zijlmans HJMAA; Fons G; van de Vijver KK; Bleeker MCG; Kenter GG; Jordanova EJ; de Gruijl TD
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34697217
[TBL] [Abstract][Full Text] [Related]
6. Cervicovaginal Microbiome Factors in Clearance of Human Papillomavirus Infection.
Dai W; Du H; Li S; Wu R
Front Oncol; 2021; 11():722639. PubMed ID: 34395294
[TBL] [Abstract][Full Text] [Related]
7. The interplay between the vaginal microbiome and innate immunity in the focus of predictive, preventive, and personalized medical approach to combat HPV-induced cervical cancer.
Kudela E; Liskova A; Samec M; Koklesova L; Holubekova V; Rokos T; Kozubik E; Pribulova T; Zhai K; Busselberg D; Kubatka P; Biringer K
EPMA J; 2021 Jun; 12(2):199-220. PubMed ID: 34194585
[TBL] [Abstract][Full Text] [Related]
8. Theta-Defensins Inhibit High-Risk Human Papillomavirus Infection Through Charge-Driven Capsid Clustering.
Skeate JG; Segerink WH; Garcia MD; Fernandez DJ; Prins R; Lühen KP; Voss FO; Da Silva DM; Kast WM
Front Immunol; 2020; 11():561843. PubMed ID: 33154746
[TBL] [Abstract][Full Text] [Related]
9. Human genetic dissection of papillomavirus-driven diseases: new insight into their pathogenesis.
Béziat V
Hum Genet; 2020 Jun; 139(6-7):919-939. PubMed ID: 32435828
[TBL] [Abstract][Full Text] [Related]
10. The Essential Role of anxA2 in Langerhans Cell Birbeck Granules Formation.
Thornton SM; Samararatne VD; Skeate JG; Buser C; Lühen KP; Taylor JR; Da Silva DM; Kast WM
Cells; 2020 Apr; 9(4):. PubMed ID: 32326440
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?
Hasche D; Vinzón SE; Rösl F
Front Microbiol; 2018; 9():874. PubMed ID: 29770129
[TBL] [Abstract][Full Text] [Related]
12. Immunology of Uterine and Vaginal Mucosae: (Trends in Immunology 39, 302-314, 2018).
Zhou JZ; Way SS; Chen K
Trends Immunol; 2018 Apr; 39(4):355. PubMed ID: 29530651
[TBL] [Abstract][Full Text] [Related]
13. The interplay of UV and cutaneous papillomavirus infection in skin cancer development.
Hasche D; Stephan S; Braspenning-Wesch I; Mikulec J; Niebler M; Gröne HJ; Flechtenmacher C; Akgül B; Rösl F; Vinzón SE
PLoS Pathog; 2017 Nov; 13(11):e1006723. PubMed ID: 29190285
[TBL] [Abstract][Full Text] [Related]
14. Modulation of antigen presenting cell functions during chronic HPV infection.
Bashaw AA; Leggatt GR; Chandra J; Tuong ZK; Frazer IH
Papillomavirus Res; 2017 Dec; 4():58-65. PubMed ID: 29179871
[TBL] [Abstract][Full Text] [Related]
15. T cell ignorance is bliss: T cells are not tolerized by Langerhans cells presenting human papillomavirus antigens in the absence of costimulation.
Woodham AW; Yan L; Skeate JG; van der Veen D; Brand HH; Wong MK; Da Silva DM; Kast WM
Papillomavirus Res; 2016 Dec; 2():21-30. PubMed ID: 27182559
[TBL] [Abstract][Full Text] [Related]
16. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.
Skeate JG; Woodham AW; Einstein MH; Da Silva DM; Kast WM
Hum Vaccin Immunother; 2016 Jun; 12(6):1418-29. PubMed ID: 26835746
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C.
Da Silva DM; Woodham AW; Rijkee LK; Skeate JG; Taylor JR; Koopman ME; Brand HE; Wong MK; McKee GM; Salazar AM; Kast WM
Papillomavirus Res; 2015 Dec; 1():12-21. PubMed ID: 26665182
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.
Da Silva DM; Woodham AW; Naylor PH; Egan JE; Berinstein NL; Kast WM
J Interferon Cytokine Res; 2016 May; 36(5):291-301. PubMed ID: 26653678
[TBL] [Abstract][Full Text] [Related]
19. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.
Da Silva DM; Woodham AW; Skeate JG; Rijkee LK; Taylor JR; Brand HE; Muderspach LI; Roman LD; Yessaian AA; Pham HQ; Matsuo K; Lin YG; McKee GM; Salazar AM; Kast WM
Clin Immunol; 2015 Dec; 161(2):197-208. PubMed ID: 26360252
[TBL] [Abstract][Full Text] [Related]
20. Immune Dysregulation in Patients Persistently Infected with Human Papillomaviruses 6 and 11.
Lucs AV; DeVoti JA; Hatam L; Afzal A; Abramson AL; Steinberg BM; Bonagura VR
J Clin Med; 2015 Mar; 4(3):375-88. PubMed ID: 26023354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
